Merck (MRK) may have readily turned its Keytruda cancer drug into a medical and financial juggernaut, but its bid to win regulatory approval for at least one additional use may not come so easily, judging by documents from the Food and Drug Administration.
The drug maker wants to sell the medicine to combat high-risk, early-stage triple-negative breast cancer along with chemotherapy before surgery, and then by itself after surgery. An approval would further expand the market for one of the world’s hottest drugs, which is already used to combat numerous cancers. Last year, Keytruda generated $14.4 billion in sales — a 30% increase and 30% of Merck revenue.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
"breast" - Google News
February 06, 2021 at 04:12AM
https://ift.tt/39SznZ7
FDA blasts Merck's Keytruda data for new breast cancer indication - STAT
"breast" - Google News
https://ift.tt/2ImtPYC
https://ift.tt/2Wle22m
Bagikan Berita Ini
0 Response to "FDA blasts Merck's Keytruda data for new breast cancer indication - STAT"
Post a Comment